 

Term

Description

 

Scheme of Amalgamation

The scheme of amalgamation between Optival, Ritemed and their respective shareholders and creditors,
under Section 233 and certain other provisions of the Companies Act, 2013 filed with the RoC on
October 3, 2018 pursuant to which Ritemed amalgamated with Optival, as described in “History and
Certain Corporate Matters” on page 194

 

 

 

 

SBPPL Shri Banashankari Pharma Private Limited
SPDPL. Sidson Pharma Distributors Private Limited
SSPPL Sai Sridhar Pharma Private Limited

Series A CCPS. Series A CCPS of face value of 220 each

 

Series B CCPS

Series B CCPS of face value of 220 each

 

Series B1 CCPS

Series B1 CCPS of face value of 220 each

 

Series B2 CCPS

Series B2 CCPS of face value of 220 each

 

Series C1 CCPS

Series C1 CCPS of face value of 220 each

 

Series C2 CCPS

Series C2 CCPS of face value of 220 each

 

Selling Shareholders

Collectively, the Investor Selling Shareholder and the Other Selling Shareholders

 

 

 

 

SHA Shareholders agreement dated December 24, 2020 amongst our Company, our Promoters, PI
Opportunities Fund-I, S.S. Pharma LLC, Shore Pharma LLC, Natco Pharma Limited, Time Cap Pharma
Labs Private Limited, Lavender Rose Investment Ltd, Gangadi Investments Private Limited and certain
individual shareholders of our Company, as amended by waiver cum amendment agreement dated
August 5, 2021

Shareholders The holders of the Equity Shares of our Company

Stakeholders’ Relationship | The stakeholders’ relationship committee of our Board, constituted in accordance with the applicable

Committee provisions of the Companies Act, 2013 and the Listing Regulations and as described in “Our
Management” on page 195

Subsidiary Subsidiaries of our Company, as of the date of this Prospectus and as identified under the provisions of

the Companies Act, namely:

Clearancekart Private Limited;

Deccan Medisales Private Limited;

Kalyani Meditimes Private Limited;

MHS Pharmaceuticals Private Limited;
Nova Sud Pharmaceuticals Private Limited;
Optival Health Solutions Private Limited;

Sai Sridhar Pharma Private Limited;

Snr fF we

 

Shri Banashankari Pharma Private Limited;
9. Sidson Pharma Distributors Private Limited;
10. Venkata Krishna Enterprises Private Limited; and

11. Wynclark Pharmaceuticals Private Limited

 

User Agreement

User agreement dated March 1, 2019 entered into between Optival and our Company

 

 

 

VKEPL Venkata Krishna Enterprises Private Limited
WPPL. Wynclark Pharmaceuticals Private Limited
Offer Related Terms

 

Term

Description

 

‘Acknowledgement Slip

The slip or document issued by a Designated Intermediary to a Bidder as proof of registration of the Bid
cum Application Form

 

“Allot” “Allotment”

“Allotted”

or or

Unless the context otherwise requires, allotment of the Equity Shares pursuant to the Fresh Issue and
transfer of the Offered Shares pursuant to the Offer for Sale to the successful Bidders

 

Allotment Advice

Note or advice or intimation of Allotment sent to the successful Bidders who have been or are to be
Allotted the Equity Shares after the Basis of Allotment has been approved by the Designated Stock
Exchange

 

Allottee

A successful Bidder to whom the Equity Shares are Allotted

 

Anchor Investor

A Qualified Institutional Buyer, who applied under the Anchor Investor Portion in accordance with the
requirements specified in the SEBI ICDR Regulations and the Red Herring Prospectus and this
Prospectus who has Bid for an amount of at least 7100 million

 

Anchor Investor Allocation Price

 

 

2796 per Equity Share being the Price at which Equity Shares were allocated to the Anchor Investors in
terms of the Red Herring Prospectus and this Prospectus, which was decided by our Company and the
Investor Selling Shareholder, in consultation with the BRLMs

 

 
